1887

Chapter 35 : Immunotherapy

Authors: Brahm H. Segal1, Luigina R. Romani2
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Dept. of Medicine and Dept. of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263; 2: Microbiology Section, Dept. of Experimental Medicine, University of Perugia, Perugia, Italy
Content Type: Monograph
Publication Year: 2009

Category: Clinical Microbiology; Fungi and Fungal Pathogenesis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Immunotherapy, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap35-1.gif /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap35-2.gif

Abstract:

Immunotherapeutic strategies for invasive aspergillosis should be understood in the context of host defense deficits in high-risk patients and immunopathology of fungal disease. This chapter discusses the following strategies for immunotherapy for invasive aspergillosis: (i) augmentation of neutrophil number; (ii) pathogen recognition receptor (PRR) ligands; (iii) cytokine administration and depletion; and (iv) vaccination. Price et al. conducted a phase I / II study of granulocyte transfusions derived from unrelated, non- HLA-matched, community donors following G-CSF and dexamethasone mobilization. Eight of 11 patients with bacterial infections or candidemia survived, but all 8 patients with invasive mold infection died. This study showed the safety and feasibility of using community donors for granulocytapheresis donations. The Transfusion Medicine and Hemostasis Network of the National Heart, Lung and Blood Institute is in the planning stages of a randomized study of adjunctive granulocyte transfusions in neutropenic patients with severe bacterial and fungal infections. This study is expected to definitively evaluate the benefits and risks of adjunctive granulocyte transfusions. There are several potential cytokines and chemokines that can be exploited as immunotherapy for invasive aspergillosis. Adoptive transfer of Th1-committed CD4T cells conferred protection to neutropenic mice, establishing a proof of principle regarding cellular immunity as a target for immune augmentation in invasive aspergillosis. This study also showed that the dichotomy in which the host defense against extracellular pathogens is humoral while the defense against intracellular pathogens is cellular is overly simplistic. Antifungal agents have immunomodulatory effects that may be clinically relevant and exploitable for immunotherapeutic strategies.

Citation: Segal B, Romani L. 2009. Immunotherapy, p 467-478. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch35
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Immunotherapy
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815523.ch35-1,webId=/content/author/10.1128/9781555815523.ch35-1,properties={foaf_givenname=Brahm H., foaf_name=Brahm H. Segal, foaf_surname=Segal, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815523.ch35-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815523.ch35-2,webId=/content/author/10.1128/9781555815523.ch35-2,properties={foaf_givenname=Luigina R., foaf_name=Luigina R. Romani, foaf_surname=Romani, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815523.ch35-aff2]]}]]
Citation: Segal B, Romani L. 2009. Immunotherapy, p 467-478. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch35
/content/10.1128/9781555815523.ch35.ch35fig01
Figure 1.
Model of contribution of T cells to host defense and inflammation against .
10.1128/9781555815523/f0473-01_thmb.gif
10.1128/9781555815523/f0473-01.gif
Image of Figure 1.
Figure 1.

Model of contribution of T cells to host defense and inflammation against .

Citation: Segal B, Romani L. 2009. Immunotherapy, p 467-478. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch35
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815523.ch35
1. Anonymous. 1991. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N. Engl. J. Med. 324: 509– 516.
2. Arning, M.,, K. O. Kliche,, A. H. Heer-Sonderhoff, and, A. Wehmeier. 1995. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38: 459– 465.
3. Baddley, J. W.,, T. P. Stroud,, D. Salzman, and, P. G. Pappas. 2001. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. 32: 1319– 1324.
4. Balloy, V.,, M. Huerre,, J. P. Latge, and, M. Chignard. 2005. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect. Immun. 73: 494– 503.
5. Belladonna, M. L.,, U. Grohmann,, P. Guidetti,, C. Volpi,, R. Bianchi,, M. C. Fioretti,, R. Schwarcz,, F. Fallarino, and, P. Puccetti. 2006. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 177: 130– 137.
6. Bellocchio, S.,, R. Gaziano,, S. Bozza,, G. Rossi,, C. Montagnoli,, K. Perruccio,, M. Calvitti,, L. Pitzurra, and, L. Romani. 2005. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55: 214– 222.
7. Bellocchio, S.,, S. Moretti,, K. Perruccio,, F. Fallarino,, S. Bozza,, C. Montagnoli,, P. Mosci,, G. B. Lipford,, L. Pitzurra, and, L. Romani. 2004. TLRs govern neutrophil activity in aspergillosis. J. Immunol. 173: 7406– 7415.
8. Bensinger, W. I.,, T. H. Price,, D. C. Dale,, F. R. Appelbaum,, R. Clift,, K. Lilleby,, B. Williams,, R. Storb,, E. D. Thomas, and, C. D. Buckner. 1993. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81: 1883– 1888.
9. Berenguer, J.,, M. C. Allende,, J. W. Lee,, K. Garrett,, C. Lyman,, N. M. Ali,, J. Bacher,, P. A. Pizzo, and, T. J. Walsh. 1995. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am. J. Respir. Crit. Care Med. 152: 1079– 1086.
10. Bhatia, S.,, J. McCullough,, E. H. Perry,, M. Clay,, N. K. Ramsay, and, J. P. Neglia. 1994. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 34: 226– 232.
11. Bignell, E.,, S. Negrete-Urtasun,, A. M. Calcagno,, H. N. Arst, Jr.,, T. Rogers, and, K. Haynes. 2005. Virulence comparisons of Aspergillus nidulans mutants are confounded by the inflammatory response of p47 phox-i- mice lnfect. Immun. 73: 5204– 5207.
12. BitMansour, A.,, S. M. Burns,, D. Traver,, K. Akashi,, C. H. Contag,, I. L. Weissman, and, J. M. Brown. 2002. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood 100: 4660– 4667.
13. Bozza, S.,, R. Gaziano,, G. B. Lipford,, C. Montagnoli,, A. Bacci,, P. Di Francesco,, V. P. Kurup,, H. Wagner, and, L. Romani. 2002. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 4: 1281– 1290.
14. Bozza, S.,, K. Perruccio,, C. Montagnoli,, R. Gaziano,, S. Bellocchio,, E. Burchielli,, G. Nkwanyuo,, L. Pitzurra,, A. Velardi, and, L. Romani. 2003. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 5: 5.
15. Brown, G. D. 2006. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat. Rev. Immunol. 6: 33– 43.
16. Brown, G. D., and, S. Gordon. 2001. Immune recognition. A new receptor for beta-glucans. Nature 413: 36– 37.
17. Brown, G. D.,, J. Herre,, D. L. Williams,, J. A. Willment,, A. S. Marshall, and, S. Gordon. 2003. Dectin-1 mediates the biological effects of beta-glucans. J. Exp. Med. 197: 1119– 1124.
18. Brown, G. D.,, P. R. Taylor,, D. M. Reid,, J. A. Willment,, D. L. Williams,, L. Martinez-Pomares,, S. Y. Wong, and, S. Gordon. 2002. Dectin-1 is a major beta-glucan receptor on macrophages. J. Exp. Med. 196: 407– 412.
19. Cenci, E.,, A. Mencacci,, A. Bacci,, F. Bistoni,, V. P. Kurup, and, L. Romani. 2000. T cell vaccination in mice with invasive pulmonary aspergillosis. J. Immunol. 165: 381– 388.
20. Cenci, E.,, A. Mencacci,, G. Del Sero,, A. Bacci,, C. Montagnoli,, C. F. d’Ostiani,, P. Mosci,, M. Bachmann,, F. Bistoni,, M. Kopf, and, L. Romani. 1999. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J. Infect. Dis. 180: 1957– 1968.
21. Cenci, E.,, S. Perito,, K. H. Enssle,, P. Mosci,, J. P. Latge,, L. Romani, and, F. Bistoni. 1997. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect. Immun. 65: 564– 570.
22. Chamilos, G.,, M. Luna,, R. E. Lewis,, G. P. Bodey,, R. Chemaly,, J. J. Tarrand,, A. Safdar,, I. I. Raad, and, D. P. Kontoyiannis. 2006. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91: 986– 989.
23. Chang, Y. C,, B. H. Segal,, S. M. Holland,, G. F. Miller, and, K. J. Kwon-Chung. 1998. Virulence of catalase-deficient aspergillus ni-dulans in p47 phox-/- mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease. J. Clin. Investig. 101: 1843– 1850.
24. Cohen, M. S.,, R. E. Isturiz,, H. L. Malech,, R. K. Root,, C. M. Wilfert,, L. Gutman, and, R. H. Buckley. 1981. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am. J. Med. 71: 59– 66.
25. Comely, O. A.,, J. Maertens,, D. J. Winston,, J. Perfect,, A. J. Ullmann,, T. J. Walsh,, D. Helfgott,, J. Holowiecki,, D. Stockelberg,, Y. T. Goh,, M. Petrini,, C. Hardalo,, R. Suresh, and, D. Angulo-Gonzalez. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356: 348– 359.
26. Dale, D. C,, W. C. Liles,, C. Llewellyn,, E. Rodger, and, T. H. Price. 1998. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexa-methasone. Transfusion 38: 713– 721.
27. Dekker, A.,, S. Bulley,, J. Beyene,, L. L. Dupuis,, J. J. Doyle, and, L. Sung. 2006. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and alloge-neic stem cell transplantation. J. Clin. Oncol. 24: 5207– 5215.
28. Denning, D. W. 2003, posting date. Introduction: the Aspergillus fumigatus Genome Database. The Institute for Genomic Research, Rockville, MD. www.tigr.org/tdb/e2k1/afu1/intro.shtml.
29. Denning, D. W.,, A. Marinus,, J. Cohen,, D. Spence,, R. Herbrecht,, L. Pagano,, C. Kibbler,, V. Kcrmery,, F. Offner,, C. Cordonnier,, U. Jehn,, M. Ellis,, L. Collette,, R. Sylvester, et al. 1998. An EORTC multi-centre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J. Infect. 37: 173– 180.
30. Dennis, C. G,, W. R. Greco,, Y. Brun,, R. Youn,, H. K. Slocum,, R. J. Bernacki,, R. Lewis,, N. Wiederhold,, S. M. Holland,, R. Petraitiene,, T. J. Walsh, and, B. H. Segal. 2006. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox_/_ mouse model of chronic granulomatous disease. Antimicrob. Agents Chemother. 50: 422– 427.
31. Dignani, M. C,, E. J. Anaissie,, J. P. Hester,, S. O’Brien,, S. E. Varti-varian,, J. H. Rex,, H. Kantarjian,, D. B. Jendiroba,, B. Lichtiger,, B. S. Andersson, and, E. J. Freireich. 1997. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 11: 1621– 1630.
32. Dignani, M. C,, J. H. Rex,, K. W. Chan,, G. Dow,, M. deMagalhaes-Silverman,, A. Maddox,, T. Walsh, and, E. Anaissie. 2005. Immu-nomodulation with interferon-gamma and colony stimulating factors for refractory fungal infections in patients with leukemia. Cancer 104: 199– 204.
33. Fleming, R. V.,, E. J. Anaissie,, H. M. Kantarjian,, C. Savary, and, J. H. Rex. 1997. Interferon-gamma (IFN-Γ) plus granulocyte-colony stimulating factor (G-CSF) in the treatment of refractory fungal infec- tions: a pilot study, abstr. G-31. 37th Intersci. Conf. Antimicrob. Agents Chemother., Toronto, Canada.
34. Gallin, J. I.,, D. W. Alling,, H. L. Malech,, R. Wesley,, D. Koziol,, B. Marciano,, E. M. Eisenstein,, M. L. Turner,, E. S. DeCarlo,, J. M. Starling, and, S. M. Holland. 2003. Itraconazole prophylaxis for fungal infections in chronic granulomatous disease of childhood. N. Engl. J. Med. 348: 2416– 2422.
35. Gamvrellis, A.,, D. Leong,, J. C. Hanley,, S. D. Xiang,, P. Mottram, and, M. Plebanski. 2004. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol. 82: 506– 516.
36. Gantner, B. N.,, R. M. Simmons,, S. J. Canavera,, S. Akira, and, D. M. Underhill. 2003. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 197: 1107– 1117.
37. Garlanda, C.,, E. Hirsch,, S. Bozza,, A. Salustri,, M. De Acetis,, R. Nota,, A. Maccagno,, F. Riva,, B. Bottazzi,, G. Peri,, A. Doni,, L. Vago,, M. Botto,, R. De Santis,, P. Carminati,, G. Siracusa,, F. Altruda,, A. Vec-chi,, L. Romani, and, A. Mantovani. 2002. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420: 182– 186.
38. Gaziano, R.,, S. Bozza,, S. Bellocchio,, K. Perruccio,, C. Montagnoli,, L. Pitzurra,, G. Salvatori,, R. De Santis,, P. Carminati,, A. Mantovani, and, L. Romani. 2004. Anti- Aspergillus fumigatus efficacy of pen-traxin 3 alone and in combination with antifungals. Antimicrob. Agents Chemother. 48: 4414– 4421.
39. Gerson, S. L.,, G. H. Talbot,, S. Hurwitz,, B. L. Strom,, E. J. Lusk, and, P. A. Cassileth. 1984. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann. Intern. Med. 100: 345– 351.
40. Gersuk, G. M.,, D. M. Underhill,, L. Zhu, and, K. A. Marr. 2006. Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J. Immunol. 176: 3717– 3724.
41. Graham, L. M.,, S. V. Tsoni,, J. A. Willment,, D. L. Williams,, P. R. Taylor,, S. Gordon,, K. Dennehy, and, G. D. Brown. 2006. Soluble dectin-1 as a tool to detect beta-glucans. J. Immunol. Methods 314: 164– 169.
42. Grow, W. B.,, J. S. Moreb,, D. Roque,, K. Manion,, H. Leather,, V. Reddy,, S. A. Khan,, K. J. Finiewicz,, H. Nguyen,, C. J. Clancy,, P. S. Mehta, and, J. R. Wingard. 2002. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 29: 15– 19.
43. Herbrecht, R.,, D. W. Denning,, T. F. Patterson,, J. E. Bennett,, R. E. Greene,, J. W. Oestmann,, W. V. Kern,, K. A. Marr,, P. Ribaud,, O. Lortholary,, R. Sylvester,, R. H. Rubin,, J. R. Wingard,, P. Stark,, C. Durand,, D. Caillot,, E. Thiel,, P. H. Chandrasekar,, M. R. Hodges,, H. T. Schlamm,, P. F. Troke, and, B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347: 408– 415.
44. Hogaboam, C. M.,, K. Takahashi,, R. A. Ezekowitz,, S. L. Kunkel, and, J. M. Schuh. 2004. Mannose-binding lectin deficiency alters the development of fungal asthma: effects on airway response, inflammation, and cytokine profile. J. Leukoc. Biol. 75: 805– 814.
45. Hohl, T. M.,, H. L. Van Epps,, A. Rivera,, L. A. Morgan,, P. L. Chen,, M. Feldmesser, and, E. G. Pamer. 2005. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog. 1: e30.
46. Holland, S. M.,, E. M. Eisenstein,, D. B. Kuhns,, M. L. Turner,, T. A. Fleisher,, W. Strober, and, J. I. Gallin. 1994. Treatment of refractory disseminated nontuberculous mycobacterial infection with inter-feron gamma. A preliminary report. N. Engl. J. Med. 330: 1348– 1355.
47. Jantunen, E.,, P. Ruutu,, L. Niskanen,, L. Volin,, T. Parkkali,, P. Koukila-Kahkola, and, T. Ruutu. 1997. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 19: 801– 808.
48. Lemaitre, B.,, E. Nicolas,, L. Michaut,, J. M. Reichhart, and, J. A. Hoffmann. 1996. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86: 973– 983.
49. Lewis, R. E.,, G. Chamilos,, R. A. Prince, and, D. P. Kontoyiannis. 2007. Pretreatment with empty liposomes attenuates the immuno-pathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob. Agents Chemother. 51: 1078– 1081.
50. Ley, K.,, E. Smith, and, M. A. Stark. 2006. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol. Res. 34: 229– 242.
51. Marr, K. A.,, R. A. Carter,, M. Boeckh,, P. Martin, and, L. Corey. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100: 4358– 4366.
52. Martino, R.,, M. Subira,, M. Rovira,, C. Solano,, L. Vazquez,, G. F. Sanz,, A. Urbano-Ispizua,, S. Brunet, and, R. De la Camara. 2002. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Hae-matol. 116: 475– 482.
53. McNeil, M. M.,, S. L. Nash,, R. A. Hajjeh,, M. A. Phelan,, L. A. Conn,, B. D. Plikaytis, and, D. W. Warnock. 2001. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin. Infect. Dis. 33: 641– 647.
54. McWhinney, P. H.,, C. C. Kibbler,, M. D. Hamon,, O. P. Smith,, L. Gandhi,, L. A. Berger,, R. K. Walesby,, A. V. Hoffbrand, and, H. G. Prentice. 1993. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years’ experience. Clin. Infect. Dis. 17: 397– 404.
55. Mellor, A. L., and, D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762– 774.
56. Montagnoli, C.,, F. Fallarino,, R. Gaziano,, S. Bozza,, S. Bellocchio,, T. Zelante,, W. P. Kurup,, L. Pitzurra,, P. Puccetti, and, L. Romani. 2006. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J. Immunol. 176: 1712– 1723.
57. Montagnoli, C.,, K. Perruccio,, S. Bozza,, P. Bonifazi,, T. Zelante,, A. De Luca,, S. Moretti,, C. D’Angelo,, F. Bistoni,, M. Martelli,, F. Av-ersa,, A. Velardi, and, L. Romani. 2008. Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation. Blood Cells Mol. Dis. 40: 55– 62.
58. Mouy, R.,, F. Veber,, S. Blanche,, J. Donadieu,, R. Brauner,, J. C. Levron,, C. Griscelli, and, A. Fischer. 1994. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J. Pediatr. 125: 998– 1003.
59. Mukhopadhyay, S.,, J. Herre,, G. D. Brown, and, S. Gordon. 2004. The potential for Toll-like receptors to collaborate with other innate immune receptors. Immunology 112: 521– 530.
60. Nagai, H.,, J. Guo,, H. Choi, and, V. Kurup. 1995. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J. Infect. Dis. 172: 1554– 1560.
61. Netea, M. G.,, N. A. Gow,, C. A. Munro,, S. Bates,, C. Collins,, G. Ferwerda,, R. P. Hobson,, G. Bertram,, H. B. Hughes,, T. Jansen,, L. Jacobs,, E. T. Buurman,, K. Gijzen,, D. L. Williams,, R. Torensma,, A. McKinnon,, D. M. Maccallum,, F. C. Odds,, J. W. Van der Meer,, A. J. Brown, and, B. J. Kullberg. 2006. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J. Clin. Investig. 116: 1642– 1650.
62. Netea, M. G.,, C. A. Van Der Graaf,, A. G. Vonk,, I. Verschueren,, J. W. Van Der Meer, and, B. J. Kullberg. 2002. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. 185: 1483– 1489.
63. Nichols, W. G.,, T. Price, and, M. Boeckh. 2002. Cytomegalovirus infections in cancer patients receiving granulocyte transfusions. Blood 99: 3483– 3484.
64. Ozinsky, A.,, D. M. Underhill,, J. D. Fontenot,, A. M. Hajjar,, K. D. Smith,, C. B. Wilson,, L. Schroeder, and, A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. USA 97: 13766– 13771.
65. Pappas, P. G.,, B. Bustamante,, E. Ticona,, R. Hamill,, P. Johnson,, A. Reboli,, J. Aberg,, R. Hasbun, and, H. H. Hsu. 2004. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis. 189: 2185– 2191.
66. Peters, C,, M. Minkov,, S. Matthes-Martin,, U. Potschger,, V. Witt,, G. Mann,, P. Hocker,, N. Worel,, J. Stary,, T. Klingebiel, and, H. Gadner. 1999. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br. J. Haematol. 106: 689– 696.
67. Petraitis, V.,, R. Petraitiene,, A. H. Groll,, A. Bell,, D. P. Callender,, T. Sein,, R. L. Schaufele,, C. L. McMillian,, J. Bacher, and, T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42: 2898– 2905.
68. Price, T. H.,, R. A. Bowden,, M. Boeckh,, J. Bux,, K. Nelson,, W. C. Liles, and, D. C. Dale. 2000. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoeitic stem cell transplantation. Blood 95: 3302– 3309.
69. Reeves, E. P.,, H. Lu,, H. L. Jacobs,, C. G. Messina,, S. Bolsover,, G. Gabella,, E. O. Potma,, A. Warley,, J. Roes, and, A. W. Segal. 2002. Killing activity of neutrophils is mediated through activation of proteases by K + flux. Nature 416: 291– 297.
70. Reiner, S. L. 2007. Development in motion: helper T cells at work. Cell 129: 33– 36.
71. Rogers, P. D.,, R. E. Kramer,, S. W. Chapman, and, J. D. Cleary. 1999. Amphotericin B-induced interleukin-1fj expression in human mon-ocytic cells is calcium and calmodulin dependent. J. Infect. Dis. 180: 1259– 1266.
72. Roilides, E.,, A. Holmes,, C. Blake,, D. Venzon,, P. A. Pizzo, and, T. J. Walsh. 1994. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J. Infect. Dis. 170: 894– 899.
73. Roilides, E.,, K. Uhlig,, D. Venzon,, P. A. Pizzo, and, T. J. Walsh. 1993a. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect. Immun. 61: 1185– 1193.
74. Roilides, E.,, K. Uhlig,, D. Venzon,, P. A. Pizzo, and, T. J. Walsh. 1993b. Prevention of corticosteroid-induced suppression of human poly-morphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect. Immun. 61: 4870– 4877.
75. Romani, L.,, F. Bistoni,, R. Gaziano,, S. Bozza,, C. Montagnoli,, K. Per-ruccio,, L. Pitzurra,, S. Bellocchio,, A. Velardi,, G. Rasi,, P. Di Francesco, and, E. Garaci. 2004. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103: 4232– 4239.
76. Romani, L.,, F. Bistoni,, K. Perruccio,, C. Montagnoli,, R. Gaziano,, S. Bozza,, P. Bonifazi,, G. Bistoni,, G. Rasi,, A. Velardi,, F. Fallarino,, E. Garaci, and, P. Puccetti. 2006. Thymosin a1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 108: 2265– 2274.
77. Romani, L.,, F. Fallarino,, A. De Luca,, C. Montagnoli,, C. D’Angelo,, T. Zelante,, C. Vacca,, F. Bistoni,, M. C. Fioretti,, U. Grohmann,, B. H. Segal, and, P. Puccetti. 2008. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451: 211– 215.
78. Romani, L., and, P. Puccetti. 2007. Controlling pathogenic inflammation to fungi. Expert Rev. Anti Infect. Ther. 5: 1007– 1017.
79. Rowe, J. M. 1998. Treatment of acute myeloid leukemia with cyto-kines: effect on duration of neutropenia and response to infections. Clin. Infect. Dis. 26: 1290– 1294.
80. Rowe, J. M.,, J. W. Andersen,, J. J. Mazza,, J. M. Bennett,, E. Paietta,, F. A. Hayes,, D. Oette,, P. A. Cassileth,, E. A. Stadtmauer, and, P. H. Wiernik. 1995. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients ( >55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457– 462.
81. Safdar, A.,, G. Rodriguez,, N. Ohmagari,, D. P. Kontoyiannis,, K. V. Rolston,, I. I. Raad, and, R. E. Champlin. 2005. The safety of interferon-gamma-1b for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 103: 731– 739.
82. Segal, B. H.,, E. S. DeCarlo,, K. J. Kwon-Chung,, H. L. Malech,, J. I. Gallin, and, S. M. Holland. 1998. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 77: 345– 354.
83. Segal, B. H., and, S. M. Holland. 2003. Invasive aspergillosis in chronic granulomatous disease. The Aspergillus website. www.aspergillus.man.ac.uk.
84. Segal, B. H.,, J. Kwon-Chung,, T. J. Walsh,, B. S. Klein,, M. Battiwalla,, N. G. Almyroudis,, S. M. Holland, and, L. Romani. 2006. Immu-notherapy for fungal infections. Clin. Infect. Dis. 42: 507– 515.
85. Segal, B. H.,, T. L. Leto,, J. I. Gallin,, H. L. Malech, and, S. M. Holland. 2000. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79: 170– 200.
86. Segal, B. H., and, T. J. Walsh. 2006. Current approaches to diagnosis and treatment of invasive aspergillosis. Am. J. Respir. Crit. Care Med. 173: 707– 717.
87. Shaukat, A.,, F. Bakri,, P. Young,, T. Hahn,, D. Ball,, M. R. Baer,, M. Wetzler,, J. L. Slack,, P. Loud,, M. Czuczman,, P. L. McCarthy,, T. J. Walsh, and, B. H. Segal. 2005. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 159: 181– 188.
88. Shoham, S.,, C. Huang,, J. M. Chen,, D. T. Golenbock, and, S. M. Levitz. 2001. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166: 4620– 4626.
89. Smith, T. J.,, J. Khatcheressian,, G. H. Lyman,, H. Ozer,, J. O. Armitage,, L. Balducci,, C. L. Bennett,, S. B. Cantor,, J. Crawford,, S. J. Cross,, G. Demetri,, C. E. Desch,, P. A. Pizzo,, C. A. Schiffer,, L. Schwartz-berg,, M. R. Somerfield,, G. Somlo,, J. C. Wade,, J. L. Wade,, R. J. Winn,, A. J. Wozniak, and, A. C. Wolff. 2006. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24: 3187– 3205.
90. Spellberg, B. J.,, M. Collins,, V. Avanesian,, M. Gomez,, J. E. Edwards, Jr.,, C. Cogle,, D. Applebaum,, Y. Fu, and, A. S. Ibrahim. 2007. Optimization of a myeloid cell transfusion strategy for infected neutro-penic hosts. J. Leukoc. Biol. 81: 632– 641.
91. Spellberg, B. J.,, M. Collins,, S. W. French,, J. E. Edwards, Jr.,, Y. Fu, and, A. S. Ibrahim. 2005. A phagocytic cell line markedly improves survival of infected neutropenic mice. J. Leukoc. Biol. 78: 338– 344.
92. Steele, C,, L. Marrero,, S. Swain,, A. G. Harmsen,, M. Zheng,, G. D. Brown,, S. Gordon,, J. E. Shellito, and, J. K. Kolls. 2003. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the dectin-1 beta-glucan receptor. J. Exp. Med. 198: 1677– 1688.
93. Steele, C,, R. R. Rapaka,, A. Metz,, S. M. Pop,, D. L. Williams,, S. Gordon,, J. K. Kolls, and, G. D. Brown. 2005. The beta-glucan re- ceptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus. PLoS Pathog. 1: e42.
94. Stephens-Romero, S. D.,, A. J. Mednick, and, M. Feldmesser. 2005. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect. Immun. 73: 114– 125.
95. Stergiopoulou, T.,, E. Roilides,, M. Rowden,, B. H. Segal, and, T. J. Walsh. 2007. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am. J. Clin. Pathol. 127: 349– 355.
96. Stevens, D. A. 2004. Vaccinate against aspergillosis! A call to arms of the immune system. Clin. Infect. Dis. 38: 1131– 1136.
97. Tauszig-Delamasure, S.,, H. Bilak,, M. Capovilla,, J. A. Hoffmann, and, J. L. Imler. 2002. Drosophila MyD88 is required for the response to fungal and grampositive bacterial infections. Nat. Immunol. 3: 91– 97.
98. Tkalcevic, J.,, M. Novelli,, M. Phylactides,, J. P. Iredale,, A. W. Segal, and, J. Roes. 2000. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity 12: 201– 210.
99. Torosantucci, A.,, C. Bromuro,, P. Chiani,, F. De Bernardis,, F. Berti,, C. Galli,, F. Norelli,, C. Bellucci,, L. Polonelli,, P. Costantino,, R. Rap-puoli, and, A. Cassone. 2005. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202: 597– 606.
100. Ullmann, A. J.,, J. H. Lipton,, D. H. Vesole,, P. Chandrasekar,, A. Lang-ston,, S. R. Tarantolo,, H. Greinix,, W. Morais de Azevedo,, V. Reddy,, N. Boparai,, L. Pedicone,, H. Patino, and, S. Durrant. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356: 335– 347.
101. Underhill, D. M.,, A. Ozinsky,, A. M. Hajjar,, A. Stevens,, C. B. Wilson,, M. Bassetti, and, A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401: 811– 815.
102. van Burik, J. A.,, V. Ratanatharathorn,, D. E. Stepan,, C. B. Miller,, J. H. Lipton,, D. H. Vesole,, N. Bunin,, D. A. Wall,, J. W. Hiemenz,, Y. Satoi,, J. M. Lee, and, T. J. Walsh. 2004. Micafungin versus flu-conazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39: 1407– 1416.
103. Viriyakosol, S.,, J. Fierer,, G. D. Brown, and, T. N. Kirkland. 2005. Innate immunity to the pathogenic fungus Coccidioides posadasii is dependent on Toll-like receptor 2 and dectin-1. Infect. Immun. 73: 1553– 1560.
104. Wald, A.,, W. Leisenring,, J. A. van Burik, and, R. A. Bowden. 1997. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 175: 1459– 1466.
105. Weinberger, M.,, I. Elattar,, D. Marshall,, S. M. Steinberg,, R. L. Redner,, N. S. Young, and, P. A. Pizzo. 1992. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 71: 24– 43.
106. Winkelstein, J. A.,, M. C. Marino,, R. B. Johnston, Jr.,, J. Boyle,, J. Curnutte,, J. I. Gallin,, H. L. Malech,, S. M. Holland,, H. Ochs,, P. Quie,, R. H. Buckley,, C. B. Foster,, S. J. Chanock, and, H. Dickler. 2000. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 79: 155– 169.
107. Yuen, K. Y.,, P. C. Woo,, M. S. Ip,, R. H. Liang,, E. K. Chiu,, H. Siau,, P. L. Ho,, F. F. Chen, and, T. K. Chan. 1997. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin. Infect. Dis. 25: 37– 42.
108. Zelante, T.,, A. De Luca,, P. Bonifazi,, C. Montagnoli,, S. Bozza,, S. Moretti,, M. L. Belladonna,, C. Vacca,, C. Conte,, P. Mosci,, F. Bis-toni,, P. Puccetti,, R. A. Kastelein,, M. Kopf, and, L. Romani. 2007. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur. J. Immunol. 37: 2695– 2706.

Tables

Immunotherapy
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815523.ch35-1,webId=/content/author/10.1128/9781555815523.ch35-1,properties={foaf_givenname=Brahm H., foaf_name=Brahm H. Segal, foaf_surname=Segal, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815523.ch35-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815523.ch35-2,webId=/content/author/10.1128/9781555815523.ch35-2,properties={foaf_givenname=Luigina R., foaf_name=Luigina R. Romani, foaf_surname=Romani, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815523.ch35-aff2]]}]]
Citation: Segal B, Romani L. 2009. Immunotherapy, p 467-478. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch35
/content/10.1128/9781555815523.ch35.ch35tab01
Table 1.
Patients at risk for invasive aspergillosis
Generic image for table
Table 1.

Patients at risk for invasive aspergillosis

Citation: Segal B, Romani L. 2009. Immunotherapy, p 467-478. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch35
/content/10.1128/9781555815523.ch35.ch35tab02
Table 2.
Summary of immune augmentation strategies against aspergillosis
Generic image for table
Table 2.

Summary of immune augmentation strategies against aspergillosis

Citation: Segal B, Romani L. 2009. Immunotherapy, p 467-478. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch35

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error